Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Lol yezzir, hopefully everybody loaded the boat... might just hit 2s and drop again like a week ago
Your prediction looks like its starting today!
$NRBO Volume 1.6M Premarket
Low Float + Oversold + Short interest + Completed RS + Completed Offering $3 + Upcoming Catalyst + New insider Goldman Sachs 1.2M
Is this expected short covering bounce taking too long to materialize? Thanks
May to October average NBRO stock price might be 14. Then the investors got blindsided by a 4 fold dilutive offering at $3.00. The offering brought in $32 million or so. The dilution is four X. Taking 14 as previous fair value. Divide by 4 and no cash added considered gets you $3.50 fair value. $32 million in cash would add value to NRBO to somewhere above $3.50. Perhaps it would be $2 per share added value for cash on hand. That would add up to a ballpark $5.50 per share as a fair current price per share for NBRO.
An investor needs however to discount future reverse splits, subsequent dilutive offerings and perhaps some sort of corruption to be a real concern regarding the future value of their holdings.
Also of interest here is how likely are the investigational drugs to succeed. Does this important topic get discussed?
Yes, understandably... like i said, it will pop within the days to come... (in a normal market LOL)
"The number of outstanding shares of the registrant’s common stock, $0.001 par value, as of November 11, 2022 was 6,503,528"
https://finance.yahoo.com/sec-filing/NRBO/0001558370-22-017864_1638287
That's still not bad for a Company with $100,000,000 +++ potential.
And they added 3,145,000 for the record in a share offering for $3 as their price didn't hold $20+... so.... 4 million+ now not 800k at all.
It will pick up steam within days...
52 million shares traded in one day for NRBO with an outstanding share count of 888,000 shares. Am I mistaken to say that each outstanding share changed hands on average around 58 times in one day?
Does this seem unusual to any one else here besides me?
52,000,000+ shares traded a couple of days ago and this pos barely moved up 45% in the day.
How is that possible with an OS of only 888,000 ?
There is $32.3 million in freshly acquired cash. The market cap is listed at around $1.1 million.
Outstanding shares is 888,000. Less than one million shares.
There are three drugs in trials to treat Covid and Diabetic Neuropathy. One drug is listed as Phase 2/3 which has the potential of being a pivotal trial. There must be very little hope of any success here.
How do investors assign a fair value to NRBO?
Share price of $60 was the past!!
While it can get back there, realistically, the $3 offering price is where your short-term focus should be. They prob would have to cure cancer to see $60 again
Is there any sort of floor for a stock like NRBO? What could be an upside target for a short squeeze?
Yea when is Mul dollar
NRBO IS A GREAT MULTI-DOLLARS OPPORTUNITY.
Let's go NRBO > $$$$$
Scooped up the 1.56 shares. Finaly done with shelf placements. At least for now!
Busting a move now
NRBO: GEEEEEEZUS J. KRISTOOOO!!! What the fluck????
NEUROBO ANNOUNCES CLOSING OF $32.3 MILLION UNDERWRITTEN PUBLIC OFFERING INCLUDING FULL EXERCISE OF OVERALLOTMENT OPTION AND CONCURRENT PRIVATE PLACEMENT
NRBO | 2 hours ago
CLOSES EXCLUSIVE LICENSE OF ASSETS FROM DONG-A
BOSTON, Nov. 8, 2022 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO) ("NeuroBo" or the "Company"), a clinical-stage biotechnology company focused on therapies for cardiometabolic diseases, today announced the closing of an underwritten public offering of units with gross proceeds of approximately $17.3 million, which includes the full exercise of the underwriter's over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses payable by NeuroBo. NeuroBo also announced the closing of the concurrent private placement of Series A Convertible Preferred Stock and warrants with gross proceeds of $15 million, prior to deducting placement fees and offering expenses payable by NeuroBo.
In addition, NeuroBo today announced the closing under the license agreement with Dong-A ST Co., Ltd. ("Dong-A"), pursuant to which NeuroBo has obtained an exclusive license to develop and commercialize DA-1241 and DA-1726, which are currently being evaluated for the treatment of nonalcoholic steatohepatitis (NASH), obesity and type 2 diabetes. Under the license agreement, NeuroBo will be responsible for global development, regulatory and commercial activities other than for certain Asian-Pacific geographies. Dong-A will manufacture clinical supplies and initial commercial supplies of the product at its manufacturing facility in Korea.
The underwritten public offering was comprised of (1) 3,147,003 Class A Units, priced at a public offering price of $3.00 per Class A Unit, with each Class A Unit consisting of one share of common stock, a Series A Warrant (the "Series A Warrants") to purchase one share of common stock at an exercise price of $3.00 per share that expires on the one year anniversary following the initial exercise date and a Series B Warrant (the "Series B Warrants") to purchase one share of common stock at an exercise price of $3.00 per share that expires on the five year anniversary following the initial exercise date, and (2) 2,602,997 Class B Units, priced at a public offering price of $3.00 per Class B Unit, with each Class B Unit consisting of one share of Series B Convertible Preferred Stock, convertible into one share of common stock, one Series A Warrant and one Series B Warrant. The Series A Warrants and the Series B Warrants will only be exercisable upon stockholder approval of the exercisability of the warrants under Nasdaq rules. The stockholder meetings are expected be held on or before December 22, 2022. The conversion price of the Series B Convertible Preferred Stock issued in the transaction is fixed and does not contain any variable pricing feature or any price based anti-dilutive feature. The preferred stock issued in this transaction includes a beneficial ownership blocker but has no dividend rights (except to the extent that dividends are also paid on the common stock) or liquidation preference, and, subject to limited exceptions, has no voting rights. The securities comprising the units are immediately separable and were issued separately.
Ladenburg Thalmann & Co. Inc. acted as sole book-running manager in connection with the public offering and exclusive placement agent for the concurrent private placement.
A total of 3,147,003 shares of common stock, 2,602,997 shares of Series B Convertible Preferred Stock, and warrants to purchase up to 11,500,000 shares of common stock were issued in the underwritten public offering including the full exercise of the over-allotment option.
In the concurrent private placement, NeuroBo sold $15 million of securities consisting of Series A Convertible Preferred Stock and warrants to purchase shares of common stock to Dong-A. The private placement offering was comprised of Series A Convertible Preferred Stock, which are convertible into shares of common stock at a price of $3.00 per share, and such number of warrants as Dong-A would have received had they invested such amount in the public offering.
In addition, upon the closing of the license agreement, NeuroBo issued $22 million of its Series A Convertible Preferred Stock, which are convertible into shares of common stock at a price of $3.00 per share, as an upfront payment under the license agreement.
The Series A Convertible Preferred Stock and the warrants are not convertible or exercisable until NeuroBo's shareholders have approved the issuance of the shares underlying the Series A Convertible Preferred Stock and warrants issued and sold under the private placement and issued under the license agreement.
The terms of the Series A Convertible Preferred Stock and warrants issued in the private placement and as the upfront payment under the license agreement are substantially similar to the Series B Convertible Preferred Stock and warrants issued in the public offering, including a fixed conversion price of the preferred stock and the lack of any variable pricing feature or any price based anti-dilutive feature. The preferred stock issued in the private placement and as the upfront license payment also has no dividend rights (except to the extent that dividends are also paid on the common stock) or liquidation preference, and, subject to limited exceptions, has no voting rights.
The securities issued as part of the underwritten public offering were offered pursuant to a registration statement on Form S-1, as amended (File No. 333-267482), which was declared effective by the United States Securities and Exchange Commission ("SEC") on November 4, 2022.
The securities issued as part of the private placement and as part of the upfront license payment were offered pursuant to the exemption from registration afforded by Section 4(a)(2) under the Securities Act of 1933, as amended (the "Act") and Regulation D promulgated thereunder. Such Series A Convertible Preferred Stock, the warrants, and shares of common stock issuable upon conversion of the Series A Convertible Preferred Stock and exercise of the warrants have not been registered under the Act or applicable state securities laws, and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements.
This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The underwritten public offering is being made solely by means of a prospectus. A final prospectus relating to this offering was filed by NeuroBo with the SEC on November 7, 2022. Copies of the final prospectus can be obtained at the SEC's website at www.sec.gov or from Ladenburg Thalmann & Co. Inc., Prospectus Department, 640 Fifth Avenue, 4th Floor, New York, New York 10019 or by email at prospectus@ladenburg.com.
About NeuroBo
NeuroBo Pharmaceuticals, Inc., is a clinical-stage biotechnology company focused on therapies for cardiometabolic diseases. Its primary therapeutics programs include DA-1241 and DA-1726, DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, which promotes the release of key gut peptides GLP-1, GIP and PYY, which, in turn, play an important role in glucose metabolism, lipid metabolism and weight loss. DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring, 37-amino acid peptide hormone that is released from the gut after ingestion of a meal, activating both the GLP-1 and glucagon receptors, prompting reduced food intake as well as an increase in energy expenditure, potentially resulting in superior body weight loss compared to selective GLP-1 receptor agonists.
NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts. For more information, please visit www.neurobopharma.com.
Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements about the closing of the offering of securities. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking state
BIG MOMO today crudeoil buddy!
Chart saying $12.95 50 dma next
Those 714k shares from S-1 shelf placement went quick today. NeuroBo is flush with more cash. Share price heading back to the teens in upcoming sessions.
Just didn’t post because was a quick trade In at $9 out at $11.06 offering says $12.59 from Oct 24th so figured they were running it to get some shares sold..
NRBO gathering some momo!
NRBO moving again!!!!!
Picking back up here! 500k float?!?!
The float is 560,000... all one has to do is buy and wait LOL....
Running up now! Massive 15% gain already. Hoping it hits $30 today!
That would be fantastic!
Looks like prime for another short squeeze like PIXY yesterday with its mini float of less then 400,000 shares. See some pre market bullishness
No matter what,tomorrow will certainly be interesting lol
Pluto trip here
nrbo when you look at their exec structure very very small and focused... and where they are located..the center of diabetes research in the world. i think that this may be substantive as well as casino..time will tell..i dont think adtx will run the same way but who knows gl
NRBO adtx WOW
just goes to show,
sometimes its all about the squeeze and not fundamentals
cough cough ahem ahem..i believe you
NO, I didn't buy any of this one. But CONGRATS to those who scored nicely here TODAY!!
hey short it..you should sleep well
$NRBO not good for a blood bath in the market
these days thats a win..but i probably didnt lose as much as you and i havent lost anything yet..gonna hold a couple of days...go buy some ibm..i dont live there
Followers
|
15
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
505
|
Created
|
02/06/20
|
Type
|
Free
|
Moderators SmellMyFinger |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |